(Adnkronos) - Pelissero (Gruppo Les): “trattamento ha rivoluzionato la cura però non c’è ancora la pillolina che ci guarisce”. Moroncini (Aou Marche): “i Jak inibitri pur riconoscendo un bersaglio specifico riescono a bloccare un’ampia serie di segnali infiammatori quindi sono antinfiammatori modulatori ad ampio spettro. Sebastiani (Ao San Camillo - Forlanini): Diversi i vantaggi: “colpiscono sostante pro infiammatorie note come citochine, vengono assunte per via orale permettendo maggiore aderenza alla terapia, ed effetto favorevole insorge rapidamente e altrettanto rapidamente svanisce in caso si interrompa il trattamento”. La terapia è già disponibile in diversi centri italiani sotto forma di trial clinico. “Ma da studi già eseguiti il farmaco upadacitinib si è già dimostrato molto efficace” conclude Sebastiani.
Category
🗞
NewsTranscript
00:00Lupus erythematosus is a chronic autoimmune disease characterized by erythematous skin and mucous manifestations with sensitivity to sunlight, but which can also involve other organs such as brain and heart, joint and central nervous system.
00:19Here is the difficulty in diagnosis and treatment of this serious pathology. Thanks to the progress of research in the therapeutic field in recent years, however, the situation has radically changed.
00:29In Italy, suffering from this pathology, which can occur at any age, with a severity that varies from case to case, are about 100,000 people, mostly women in a 9 to 1 ratio compared to male sex, and that in 8 cases out of 10, at the onset of the disease, are between 15 and 45 years old.
00:46These young women are in the fertile age, even in the expression of their lives, and this creates a lot of problems. 50-60 years ago, pregnancy was absolutely not possible.
00:58Today, women affected by lupus know they can face pregnancy, which will be a little more risky, but if well controlled, it can be carried on without particular problems.
01:13It has changed in a truly revolutionary way, but there is not yet the pill that heals us.
01:20And to give important results for those who suffer from LES is oral therapy based on jacqui libiduori, already available in Italy since 2017 for the treatment of rheumatoid arthritis.
01:31On this therapy, not yet authorized for the treatment of systemic erythematous lupus, a multicentric study is underway to assess its real effectiveness.
01:40But how does this molecule, already approved for other pathologies, such as ulcerative colitis, ankylosing spondylitis, psoriasis arthritis and atopic dermatitis, actually work?
01:50There is currently a study for vitiligin and alopecia areata, as well as for LES.
01:55Jacqui libiduori are a new class of immunomodulators, let's call them that.
02:00They are small molecules that can be taken by mouth and that specifically block a certain enzyme, namely Janus kinase, which is in fact an activator of certain receptors.
02:13Our cells have a sort of antenna on their surface that receives inflammatory signals.
02:19These small molecules are able to block many receptors that transduce many different inflammatory molecules into these cells.
02:28From this point of view, they are very interesting molecules.
02:31Therefore, even recognizing a specific molecular target, they can actually block a wide range of inflammatory signals.
02:40So they are large-spectrum immunomodulators.
02:44My center is engaged in a multi-centric clinical trial to experiment the use of these molecules, in particular one of these, Lupa da Citilib,
02:53precisely to verify if these molecules have, in the lupus, an effect equal to those already in other diseases for which they are authorized, such as rheumatoid arthritis or psoriasis arthritis.
03:04In most cases, the course of the pathology is relapsing-remitting,
03:09in which phases of disease activity alternate phases of consciousness and can take different forms depending on their severity, from mild to severe.
03:18But what do Jack inhibitors differ from other relapsing therapies?
03:22First of all, from the fact that they hit targeted pathogenic mechanisms of the disease.
03:28Substances called cytokines that have a pro-inflammatory, pejorative activity on the disease itself.
03:35Another point is that they are taken orally and therefore facilitate the supply of the drug and greater adherence of the patient to the pharmacological treatment, given the simplicity of the intake.
03:49Another point is that the favorable effect arises quickly, and just as quickly, if we suspend the drug, the effect of the drug itself is reduced.
04:01The therapy with Jack inhibitors is already available at our center, in the form of a clinical trial.
04:08Soon the results will be available and, however, there are all the scientific evidence of studies of phase 1 and phase 2 prior to this,
04:17which testify that the drug can be very effective and can be an additional weapon in the treatment of patients affected by systemic lupus erythematosus.